drugset / Trial / NCT05630287
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of selpercatinib in healthy male participants. The study will last up to 59 days (Part 1) or 46 days (Part 2) including screening and 7-day safety follow-up.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2018-09-24
- Completion
- 2018-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selpercatinib | Small molecule | 100 ug | Oral |
| Subject | Selpercatinib | Small molecule | 160 mg | Oral |
| Subject | Selpercatinib | Small molecule | 165 mg | Oral |
Indications
No indication recorded.